ع
David Robson posed the question “Would you take a test to see if your life will be cut short? I did – and it changed me” in his BBC article describing how the results from an epigenetic clock assessment motivated him to alter his diet, exercise routine and daily habits in pursuit of better long-term health. The test provided an estimate of his biological age compared with his chronological one, revealing insights into his pace of aging that he found actionable. Robson, a specialist in the extremes of human behavior and physiology, framed the process as a turning point that shifted his approach to wellness without relying on speculation about unproven outcomes.
A study published in Nature Communications in December 2025 compared 14 epigenetic clocks against 174 disease outcomes and all-cause mortality in a cohort of 18,859 participants over 10 years of follow-up. The assessment found that second- and third-generation clocks such as GrimAge v2 significantly outperformed first-generation versions in predicting health risks, with the top performer showing a hazard ratio of 1.54 per standard deviation of age acceleration for mortality. According to the researchers, adding certain clocks to traditional risk factor models improved classification accuracy by more than 1 percent in 32 of the significant associations.
Further data from the Women’s Health Initiative Memory Study, detailed in a 2026 publication in The Journals of Gerontology, examined 15 epigenetic clocks in 5,844 women and linked higher epigenetic age acceleration to reduced odds of surviving to age 90. Each standard deviation increase in acceleration for newer clocks was associated with 23 to 36 percent lower odds of exceptional longevity, the study reported. The findings showed no preferential association with cognitive healthspan over general survival, underscoring the clocks’ broader ties to overall mortality rather than specific cognitive preservation.
Commercial providers have licensed clocks such as DunedinPACE for consumer testing, allowing individuals to receive reports on their pace of aging through blood samples analyzed for DNA methylation patterns. A review on epigenetic clocks from a longevity research platform noted that these tools draw on hundreds of thousands of methylation sites, with algorithms assigning weights to predict outcomes ranging from chronological age to time until death. TruDiagnostic, one company involved in licensing, has made such assessments available as part of a growing market for personalized longevity insights.
Longitudinal research in the InCHIANTI cohort, published in Nature Aging in March 2026, tracked changes in epigenetic clocks over up to 24 years among 699 adults and determined that faster acceleration in clocks like DNAmGrimAge and DunedinPACE independently predicted higher mortality risk. The analysis improved mortality prediction models when both baseline values and rates of change were included, raising concordance indices above 0.80 for the strongest performers. These results, independent of starting epigenetic age, suggest ongoing monitoring could track evolving health status over time.
Robson integrated the test outcome into a broader mindset framework drawn from his prior writing on expectation effects, where awareness of personal data influences behavior and physiology. His account highlighted practical steps taken after the results, such as increased physical activity and nutritional adjustments, that aligned with evidence linking modifiable factors to slower epigenetic aging. The experience, as detailed in the BBC, illustrates how such tests can serve as catalysts for change when interpreted alongside established health guidance rather than in isolation.
